MINDACT in the News
News, videos, social media and more about the recently released Read More
Agendia Appoints Dr. M. William Audeh to Chief Medical Officer
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader Read More
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Read More
Agendia’s MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 Read More
Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics
PUBLICATION: Breast Cancer Res Treat (2016) 156: 279. https://doi.org/10.1007/s10549-016-3764-5 AUTHORS: Read More
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays Read More
Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care
Agendia is disappointed with the recent update to the American Read More
